retatrutide safety retatrutide clinical trials Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds If retatrutide isn't FDA approved

Trina Wilcox: What are some of the biggest unanswered questions about GLP-1s and diseases

Treatment Investigation of cause and elimination if possible Prognosis Excellent Physiologic Pigmentation Etiology Normal melanocyte activity Clinical Presentation Seen in all ages Symmetric distribution over many sites, gingiva most commonly Surface architecture, texture unchanged Diagnosis History Distribution Differential Diagnosis Mucosal melanotic macule Smoking-associated melanosis Superficial malignant melanoma Treatment None Prognosis Excellent Smokers Melanosis Etiology Melanin pigmentation of oral mucosa in heavy smokers May occur in up to 1 of 5 smokers, especially females taking birth control pills or hormone replacement Melanocytes stimulated by a component in tobacco smoke Clinical Presentation Brownish discoloration of alveolar and attached labial gingiva, buccal mucosa Pigmentation is diffuse and uniformly distributed

These therapies can be particularly beneficial to those who are undergoing treatment for cancer, as theyre highly effective in helping you restore your body quickly

Existing weight-loss drugs such as Wegovy, commonly referred to a GLP-1s, mimic the effects of glucagon-like peptide-1, a hormone that regulates metabolism

Pre-treatment: Measure morning resting heart rate for 7 days Consider baseline ECG if not done recently Review all medications for cardiac interactions Discuss with physician specifically about the glucagon receptor heart rate effect During treatment: Measure resting heart rate daily during dose escalation Continue at each dose for minimum 6 to 8 weeks before increasing If resting HR exceeds baseline by more than 10 BPM, hold dose If resting HR exceeds 90 BPM at rest consistently, consult physician before any further increases Consider microdosing approach for ultra-gradual escalation Expected timeline: Weeks 1-12: very gradual heart rate change at low doses Weeks 12-30: moderate increase as dose slowly climbs Weeks 30+: stabilization (may occur later than standard protocol due to slower escalation) Protocol 3: monitoring-enhanced approach for data-driven researchers Who this is for: Researchers who want comprehensive data, athletes tracking performance metrics, anyone who finds data reassuring